Eli Lilly begins executive search as neuro chief Anne White retires

Eli Lilly (NYSE:LLY) announced Wednesday that an executive search is underway to find an internal or external replacement for Anne White, the Indiana-based pharma giant’s executive vice president and president of its neuroscience division, who is retiring after a 30-year tenure.

White, who joined LLY in 1992, led the company’s neuro unit to receive U.S. FDA approval for its Alzheimer’s therapy Kisunla last year. Before that, she was behind LLY’s $8B acquisition of Loxo Oncology in 2019 when she was leading the company’s cancer division.

White will continue to function in her role and as a member of Lilly's Executive Committee until her retirement date on Dec. 31, 2025, the company said.

"As leader of Lilly Neuroscience, Anne led the global launch of our first-ever Alzheimer's treatment," noted CEO David Ricks, adding that “On behalf of our Board, leadership team, and thousands of employees she has touched, I would like to thank Anne for her service to our company and our mission."